Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

GLAXO EXEC VP INGRAM ASSUMES RESPONSIBILITY FOR U.S. DRUG BUSINESSES, in an "organizational realignment" effective Jan. 1, 1993. After a one-year period heading roughly half of the Glaxo U.S. drug business, Ingram is moving up a step to take senior executive authority for all sales, marketing and manufacturing of the U.S. subsidiary. The move reinforces the appearance that Ingram is being groomed as the likely successor to Glaxo Inc. Chairman Charles Sanders. Ingram continues to report to Sanders in his new role. Previously, Ingram headed the Glaxo Pharmaceuticals strategic business unit, with responsibility for Zantac, Fortaz and the company's newer central nervous system agents including Zofran and the soon-to-be-approved Imitrex (sumatriptan) migraine treatment. The Allen & Hanbury's strategic business unit, handling Glaxo's asthma line and Ceftin, has been headed by Tom D'Alonzo. That unit, still under D'Alonzo, will now report to Ingram, as will the Technical Operations strategic business unit, under Clifford Disbrow. Ingram's advancement was announced Dec. 18, coinciding ironically with the management changes at Merck (see preceding T&G). Before joining Glaxo, Ingram was one of the group of execs being groomed by Merck Chairman Vagelos for elevation into senior management and an eventual shot at the Merck chief operating officer position.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts